We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Mannkind Corp (MNKD) USD0.01

Sell:$4.15 Buy:$4.37 Change: $0.25 (5.66%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Sell:$4.15
Buy:$4.37
Change: $0.25 (5.66%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Sell:$4.15
Buy:$4.37
Change: $0.25 (5.66%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.

Contact details

Address:
30930 Russell Ranch Rd Ste 300
WESTLAKE VILLAGE
91362-7379
United States
Telephone:
+1 (818) 6615000
Website:
www.mannkindcorp.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MNKD
ISIN:
US56400P7069
Market cap:
$1.09 billion
Shares in issue:
251.26 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Castagna
    Chief Executive Officer, Director
  • Steven Binder
    Chief Financial Officer
  • Stuart Tross
    Chief People and Workplace Officer
  • David Thomson
    Executive Vice President, General Counsel, Secretary
  • Joseph Kocinsky
    Chief Technology Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.